Henning Walczak

List of Publications by Year
in descending order

185	35,416	4960 84	4015 176
papers	citations	h-index	g-index

191	191	191	35338
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
2	Tumoricidal activity of tumor necrosis factorâ€“related apoptosisâ€“inducing ligand in vivo. Nature Medicine, 1999, 5, 157-163.	30.7	2,377
3	Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 1995, 373, 438-441.	27.8	1,625
4	Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature Reviews Molecular Cell Biology, 2014, 15, 135-147.	37.0	1,373
5	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
6	TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO Journal, 1997, 16, 5386-5397.	7.8	1,012
7	Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature, 1995, 375, 497-500.	27.8	1,002
8	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	11.2	811
9	Linear ubiquitination prevents inflammation and regulates immune signalling. Nature, 2011, 471, 591-596.	27.8	805
10	FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2. Immunity, 2000, 12, 599-609.	14.3	748
11	Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.. Journal of Experimental Medicine, 1995, 182, 1223-1230.	8.5	721
12	Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex andÂIs Required for TNF-Mediated Gene Induction. Molecular Cell, 2009, 36, 831-844.	9.7	674
13	CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal of Clinical Investigation, 2003, 111, 1133-1145.	8.2	674
14	Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.. Journal of Clinical Investigation, 1997, 99, 403-413.	8.2	653
15	Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family. Journal of Experimental Medicine, 1997, 186, 1165-1170.	8.5	594
16	The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems. Experimental Cell Research, 2000, 256, 58-66.	2.6	586
17	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 2017, 9, .	12.4	512
18	Two independent pathways of regulated necrosis mediate ischemiaâ€“reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12024-12029.	7.1	485

#	Article	IF	Citations
19	Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer, 2017, 17, 352-366.	28.4	438
20	Cell nucleus and DNA fragmentation are not required for apoptosis.. Journal of Cell Biology, 1994, 127, 15-20.	5.2	419
21	TRAIL signalling: Decisions between life and death. International Journal of Biochemistry and Cell Biology, 2007, 39, 1462-1475.	2.8	408
22	Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation, 2014, 21, 1350-1364.	11.2	392
23	Caspase-8 and Bid: Caught in the act between death receptors and mitochondria. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 558-563.	4.1	384
24	The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity. Molecular Cell, 2012, 46, 746-758.	9.7	336
25	Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal, 2002, 21, 4520-4530.	7.8	303
26	Onto better TRAILs for cancer treatment. Cell Death and Differentiation, 2016, 23, 733-747.	11.2	259
27	Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene, 2000, 19, 5477-5486.	5.9	257
28	Following TRAILâ€™s path in the immune system. Immunology, 2009, 127, 145-154.	4.4	254
29	Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Research, 2000, 60, 553-9.	0.9	244
30	The Role of APO-1-Mediated Apoptosis in the Immune System. Immunological Reviews, 1994, 142, 175-191.	6.0	243
31	LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes. Cell Reports, 2015, 13, 2258-2272.	6.4	238
32	TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. ELife, 2014, 3, .	6.0	232
33	NF-Î²B-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas/FasL Is Crucial for Efficient Influenza Virus Propagation. Journal of Biological Chemistry, 2004, 279, 30931-30937.	3.4	220
34	Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nature Medicine, 2004, 10, 389-395.	30.7	217
35	HOIP Deficiency Causes Embryonic Lethality by Aberrant TNFR1-Mediated Endothelial Cell Death. Cell Reports, 2014, 9, 153-165.	6.4	217
36	Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus. Immunity, 2001, 15, 997-1009.	14.3	203

#	Article	IF	Citations
37	TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF-ÎºB and to Prevent TNF-induced Apoptosis. Journal of Biological Chemistry, 2009, 284, 35906-35915.	3.4	202
38	TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunological Reviews, 2011, 244, 9-28.	6.0	200
39	TBK1 and IKKÎµ prevent TNF-induced cell death by RIPK1 phosphorylation. Nature Cell Biology, 2018, 20, 1389-1399.	10.3	198
40	Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs. Clinical Cancer Research, 2006, 12, 2640-2646.	7.0	197
41	Ubiquitin in the immune system. EMBO Reports, 2014, 15, 28-45.	4.5	193
42	Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death and Differentiation, 2008, 15, 762-772.	11.2	191
43	The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Molecular Cell, 2017, 65, 730-742.e5.	9.7	189
44	Mitochondrial permeabilization engages NF-ÎºB-dependent anti-tumour activity under caspaseÂdeficiency. Nature Cell Biology, 2017, 19, 1116-1129.	10.3	181
45	The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 125-132.	4.1	178
46	Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation. Cold Spring Harbor Perspectives in Biology, 2013, 5, a008698-a008698.	5.5	177
47	The promise of TRAILâ€"potential and risks of a novel anticancer therapy. Journal of Molecular Medicine, 2007, 85, 923-935.	3.9	175
48	Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. Cancer Cell, 2015, 27, 561-573.	16.8	173
49	LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature, 2018, 557, 112-117.	27.8	168
50	Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology, 2005, 42, 588-597.	7.3	165
51	Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Research, 2000, 60, 3051-7.	0.9	164
52	TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Journal of Clinical Investigation, 2008, 118, 100-110.	8.2	159
53	NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-ÎºB-Dependent and -Independent Functions. Immunity, 2016, 44, 553-567.	14.3	157
54	CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-ÎºB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene, 2001, 20, 4258-4269.	5.9	154

#	Article	IF	Citations
55	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 7059-7066.	0.9	151
56	Necroptosis in Immunity and Ischemia-Reperfusion Injury. American Journal of Transplantation, 2013, 13, 2797-2804.	4.7	150
57	T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine, 2002, 8, 1433-1437.	30.7	149
58	Structure of the human APO-1 gene. European Journal of Immunology, 1994, 24, 3057-3062.	2.9	148
59	Holding RIPK1 on the Ubiquitin Leash in TNFR1 Signaling. Trends in Cell Biology, 2016, 26, 445-461.	7.9	146
60	Targeting XIAP Bypasses Bcl-2â€“Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo. Cancer Research, 2008, 68, 7956-7965.	0.9	143
61	Generation and physiological roles of linear ubiquitin chains. BMC Biology, 2012, 10, 23.	3.8	143
62	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research, 2009, 69, 2425-2434.	0.9	140
63	Linear ubiquitination: a newly discovered regulator of cell signalling. Trends in Biochemical Sciences, 2013, 38, 94-102.	7.5	133
64	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	1.3	130
65	Poly-ubiquitination in TNFR1-mediated necroptosis. Cellular and Molecular Life Sciences, 2016, 73, 2165-2176.	5.4	130
66	Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death and Disease, 2013, 4, e719-e719.	6.3	129
67	Linear ubiquitination in immunity. Immunological Reviews, 2015, 266, 190-207.	6.0	124
68	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell, 2017, 32, 342-359.e10.	16.8	122
69	SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. Cell Reports, 2016, 16, 2271-2280.	6.4	118
70	Lidocaine Induces Apoptosis via the Mitochondrial Pathway Independently of Death Receptor Signaling. Anesthesiology, 2007, 107, 136-143.	2.5	117
71	Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Induced Apoptosis. Clinical Cancer Research, 2007, 13, 3403-3412.	7.0	115
72	Is TRAIL the holy grail of cancer therapy?. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 607-623.	4.9	115

#	Article	IF	Citations
73	TRAIL: a multifunctional cytokine. Frontiers in Bioscience - Landmark, 2007, 12, 3813.	3.0	114
74	Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Molecular and Cellular Biology, 2003, 23, 777-790.	2.3	109
75	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 2007, 45, 649-658.	7.3	108
76	Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain. Journal of Neuroscience, 2002, 22, RC209-RC209.	3.6	106
77	Herpes Simplex Virus Type 1 Infection of Activated Cytotoxic T Cells. Journal of Experimental Medicine, 1999, 190, 1103-1114.	8.5	104
78	CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene, 2001, 20, 4128-4137.	5.9	104
79	Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells. Gastroenterology, 2014, 146, 278-290.	1.3	101
80	Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death and Differentiation, 2014, 21, 491-502.	11.2	100
81	Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clinical Cancer Research, 2002, 8, 3734-40.	7.0	100
82	Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Letters, 2000, 471, 93-98.	2.8	99
83	TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus. Journal of Immunology, 2003, 170, 1814-1821.	0.8	97
84	The linear ubiquitin chain assembly complex regulates <scp>TRAIL</scp>â€induced gene activation and cellÂdeath. EMBO Journal, 2017, 36, 1147-1166.	7.8	90
85	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene, 2008, 27, 3211-3220.	5.9	89
86	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. International Journal of Cancer, 2004, 109, 281-290.	5.1	85
87	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligandâ€“mediated apoptosis. Blood, 2000, 96, 2628-2631.	1.4	84
88	TRAIL and its receptors in the colonic epithelium: A putative role in the defense of viral infections. Gastroenterology, 2002, 122, 659-666.	1.3	84
89	UBE2L3 Polymorphism Amplifies NF-ÎºB Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases. American Journal of Human Genetics, 2015, 96, 221-234.	6.2	84
90	LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. Nature Communications, 2018, 9, 3910.	12.8	81

#	Article	IF	Citations
91	TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. Advances in Experimental Medicine and Biology, 2009, 647, 195-206.	1.6	80
92	ÂÂLUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. Journal of Experimental Medicine, 2016, 213, 2671-2689.	8.5	79
93	Letter to the Editor. Cell Death and Differentiation, 1999, 6, 821-822.	11.2	75
94	Polymeric Substrates with Tunable Elasticity and Nanoscopically Controlled Biomolecule Presentation. Langmuir, 2010, 26, 15472-15480.	3.5	75
95	Cell Death and Inflammation â€“ A Vital but Dangerous Liaison. Trends in Immunology, 2019, 40, 387-402.	6.8	73
96	Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. Journal of Molecular Medicine, 2009, 87, 995-1007.	3.9	72
97	Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. British Journal of Cancer, 2010, 102, 1707-1716.	6.4	70
98	TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene, 2015, 34, 2138-2144.	5.9	65
99	Linear ubiquitination at a glance. Journal of Cell Science, 2019, 132, .	2.0	65
100	APO-1(CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. International Immunology, 1995, 7, 1873-1884.	4.0	64
101	Biochemistry and function of the DISC. Trends in Biochemical Sciences, 2001, 26, 452-453.	7.5	64
102	The Emerging Role of Linear Ubiquitination in Cell Signaling. Science Signaling, 2011, 4, re5.	3.6	64
103	Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death and Differentiation, 1995, 2, 163-71.	11.2	64
104	Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5158-5163.	7.1	63
105	NF-Î²B Inhibition Reveals Differential Mechanisms of TNF Versus TRAIL-Induced Apoptosis Upstream or at the Level of Caspase-8 Activation Independent of cIAP2. Journal of Investigative Dermatology, 2008, 128, 1134-1147.	0.7	61
106	Critical role for mitochondria in B cell receptor-mediated apoptosis. European Journal of Immunology, 2000, 30, 69-77.	2.9	59
107	TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2. Journal of Investigative Dermatology, 2003, 121, 149-155.	0.7	59
108	Prognostic Value of Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clinical Cancer Research, 2009, 15, 650-659.	7.0	59

#	Article	IF	Citations
109	Death receptors as targets for antiâ€cancer therapy. Journal of Cellular and Molecular Medicine, 2008, 12, 2566-2585.	3.6	58
110	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell, 2020, 77, 970-984.e7.	9.7	54
111	Biochemical Analysis of the Native TRAIL Death-Inducing Signaling Complex. , 2008, 414, 221-239.		54
112	A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation. European Journal of Immunology, 1998, 28, 2373-2383.	2.9	53
113	Activated Tâ€„killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-Î±. European Journal of Immunology, 2004, 34, 1762-1770.	2.9	53
114	Cezanne Regulates Inflammatory Responses to Hypoxia in Endothelial Cells by Targeting TRAF6 for Deubiquitination. Circulation Research, 2013, 112, 1583-1591.	4.5	51
115	No one can whistle a symphony alone â€“ how different ubiquitin linkages cooperate to orchestrate NF-ÎºB activity. Journal of Cell Science, 2012, 125, 549-559.	2.0	50
116	M1-linked ubiquitination by LUBEL is required for inflammatory responses to oral infection in Drosophila. Cell Death and Differentiation, 2019, 26, 860-876.	11.2	50
117	Microâ€Nanostructured Protein Arrays: A Tool for Geometrically Controlled Ligand Presentation. Small, 2009, 5, 1014-1018.	10.0	49
118	Sensitive and real-time determination of H2O2 release from intact peroxisomes. Biochemical Journal, 2002, 363, 483-491.	3.7	48
119	The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics, 1992, 14, 179-180.	2.9	47
120	Regulation of Enterocyte Apoptosis by Acyl-CoA Synthetase 5 Splicing. Gastroenterology, 2007, 133, 587-598.	1.3	47
121	Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis. Nature Communications, 2016, 7, 13353.	12.8	47
122	cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-ÎºB Activation at the Death-inducing Signaling Complex in Human Keratinocytes. Journal of Biological Chemistry, 2004, 279, 52824-52834.	3.4	46
123	Caspases Target Only Two Architectural Components within the Core Structure of the Nuclear Pore Complex*. Journal of Biological Chemistry, 2006, 281, 1296-1304.	3.4	45
124	Zebrafish Model for Functional Screening of Flow-Responsive Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 130-143.	2.4	45
125	Apoptosis therapy: driving cancers down the road to ruin. Nature Medicine, 2013, 19, 131-133.	30.7	43
126	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. Journal of Experimental Medicine, 2009, 206, 1379-1393.	8.5	39

#	Article	IF	Citations
127	T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine, 2002, 8, 1433-1437.	30.7	38
128	CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues. American Journal of Pathology, 1999, 154, 193-201.	3.8	36
129	Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Journal of Experimental Medicine, 2022, 219, .	8.5	35
130	TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiotherapy and Oncology, 2006, 80, 214-222.	0.6	34
131	The Schistosoma mansoni T2 ribonuclease omega-1 modulates inflammasome-dependent IL-1Î² secretion in macrophages. International Journal for Parasitology, 2015, 45, 809-813.	3.1	34
132	Formation and removal of polyâ€ubiquitin chains in the regulation of tumor necrosis factorâ€induced gene activation and cell death. FEBS Journal, 2016, 283, 2626-2639.	4.7	34
133	In Chronic Pancreatitis, Widespread Emergence of TRAIL Receptors in Epithelia Coincides with Neoexpression of TRAIL by Pancreatic Stellate Cells of Early Fibrotic Areas. Laboratory Investigation, 2003, 83, 825-836.	3.7	32
134	Paving TRAILâ€™s Path with Ubiquitin. Trends in Biochemical Sciences, 2018, 43, 44-60.	7.5	32
135	Cutting Edge: Resistance to Apoptosis and Continuous Proliferation of Dendritic Cells Deficient for TNF Receptor-1. Journal of Immunology, 2000, 165, 4792-4796.	0.8	31
136	Sensitive and real-time determination of H2O2 release from intact peroxisomes. Biochemical Journal, 2002, 363, 483.	3.7	29
137	The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. Hepatology, 2017, 65, 1963-1978.	7.3	29
138	Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathology Research and Practice, 2010, 206, 43-50.	2.3	28
139	Transforming growth factor Î² can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology, 2005, 42, 183-192.	7.3	27
140	Death Receptors and Their Ligands in Inflammatory Disease and Cancer. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036384.	5.5	27
141	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood, 2000, 96, 2628-31.	1.4	27
142	Protective effect of Mangifera indica L. polyphenols on human T lymphocytes against activation-induced cell death. Pharmacological Research, 2007, 55, 167-173.	7.1	26
143	Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFÎºB activation via Src-dependent blockade of PP2A. Biochemical Pharmacology, 2010, 80, 439-447.	4.4	24
144	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 2013, 13, 532.	2.6	23

#	Article	IF	Citations
145	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. Cell Death and Differentiation, 2019, 26, 2710-2726.	11.2	23
146	TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Therapy, 2002, 9, 372-381.	4.6	21
147	Opposing role of tumor necrosis factor receptor 1 signaling in T cellâ€“mediated hepatitis and bacterial infection in mice. Hepatology, 2016, 64, 508-521.	7.3	21
148	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. ELife, 2018, 7, .	6.0	20
149	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1034-1046.	1.7	18
150	An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. Cell Death Discovery, 2020, 6, 14.	4.7	18
151	Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. Journal of Neuro-Oncology, 2010, 97, 171-185.	2.9	16
152	NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. Cell Death and Disease, 2016, 7, e2346-e2346.	6.3	16
153	Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. Lancet, The, 2015, 385, S9.	13.7	15
154	Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biology and Therapy, 2008, 7, 1982-1990.	3.4	14
155	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	3.3	14
156	Compound heterozygous variants in OTULIN are associated with fulminant atypical lateâ€onset ORAS. EMBO Molecular Medicine, 2022, 14, e14901.	6.9	14
157	Mangifera indica L. extract protects T cells from activation-induced cell death. International Immunopharmacology, 2006, 6, 1496-1505.	3.8	13
158	The Linear Ubiquitin Chain Assembly Complex (LUBAC) Forms Part of the TNF-R1 Signalling Complex and Is Required for Effective TNF-Induced Gene Induction and Prevents TNF-Induced Apoptosis. Advances in Experimental Medicine and Biology, 2011, 691, 115-126.	1.6	13
159	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget, 2015, 6, 10994-11008.	1.8	13
160	WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Pathology Research and Practice, 2015, 211, 109-116.	2.3	11
161	Hypochlorite-modified low-density lipoprotein induces the apoptotic machinery in Jurkat T-cell lines. Biochemical and Biophysical Research Communications, 2011, 410, 895-900.	2.1	10
162	TRAIL-receptor 2â€”a novel negative regulator of p53. Cell Death and Disease, 2021, 12, 757.	6.3	10

#	Article	IF	Citations
163	Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death and Differentiation, 2021, , .	11.2	10
164	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligandâ€“mediated apoptosis. Blood, 2000, 96, 2628-2631.	1.4	10
165	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathology Research and Practice, 2014, 210, 83-91.	2.3	9
166	Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clinical Cancer Research, 2007, 13, 6541-6542.	7.0	8
167	TLRs Go Linear â€“ On the Ubiquitin Edge. Trends in Molecular Medicine, 2017, 23, 296-309.	6.7	8
168	Thiocolchicoside a semiâ€synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?. British Journal of Pharmacology, 2012, 165, 2124-2126.	5.4	7
169	Sterile Inflammation Fuels Gastric Cancer. Immunity, 2018, 48, 481-483.	14.3	7
170	Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARSâ€CoVâ€2 mRNA vaccination. EMBO Molecular Medicine, 2022, 14, .	6.9	7
171	TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes. PLoS ONE, 2011, 6, e27171.	2.5	6
172	From Biochemical Principles of Apoptosis Induction by TRAIL to Application in Tumour Therapy. Results and Problems in Cell Differentiation, 2009, 49, 115-143.	0.7	4
173	Ubiquitin in the immune system. EMBO Reports, 2014, 15, 322-322.	4.5	4
174	Dual roles for LUBAC signaling in thymic epithelial cell development and survival. Cell Death and Differentiation, 2021, 28, 2946-2956.	11.2	4
175	Fluorogenic Substrates as Detectors of Caspase Activity During Natural Killer Cell-Induced Apoptosis. , 2000, 121, 155-162.		3
176	Death Domainâ€Containing Receptors â€“ Decisions between Suicide and Fire. , 0, , 23-36.		2
177	Endothelial Cell Killing by TAK1 Inhibition: A Novel Anti-angiogenic Strategy in Cancer Therapy. Developmental Cell, 2019, 48, 127-128.	7.0	2
178	CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a pathologenetic role for the CD95/CD95 ligand-system in ulcerative colitis. Biochemical Society Transactions, 1996, 24, 614S-614S.	3.4	0
179	We aim to refresh science, not to rebel. Nature, 1998, 393, 206-206.	27.8	0
180	Apoptosis Induction by TRAIL. , 2003, 215, 95-116.		0

#	Article	IF	Citations
181	TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika. Onkopipeline, 2010, 3, 11-23.	0.0	0
182	Regulation of Death Receptor-Induced Necroptosis by Ubiquitination. , 2014, , 79-97.		0
183	Martin Leverkus, 1965â€“2016. Cell Death Discovery, 2017, 3, 16093.	4.7	0
184	Characterization of the TNFR1-SC Using â€œModified Tandem Affinity Purificationâ€•in Conjunction with Liquid Chromatographyâ€“Mass Spectrometry (LC-MS). Methods in Molecular Biology, 2018, 1857, 161-169.	0.9	0
185	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. Journal of Cell Biology, 2009, 185, i13-i13.	5.2	0